With others shying away from the Alzheimer’s field after the many clinical implosions and disasters, Eli Lilly is still chugging along with its $2 billion deal with AC Immune — despite its share of BACE woes. AC Immune is set to receive its first milestone payment of CHF30 million, almost a year after the deal was inked. The company said that the payment “is a recognition of progress in the collaboration between the two companies and follows initiation in July 2019 of the Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomer in development for treatment of Alzheimer’s disease (AD) and other neurodegenerative disorders.” A second milestone payment of the same amount is scheduled for Q1 of 2020.